Biotech Seen Grinding Higher, Says RBC Capital (IBB)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Intercept Pharma (ICPT) Briefing Docs Raise New Questions, But All Appear Addressable - Leerink
April 5, 2016 9:33 AM EDTLeerink affirms Intercept Pharma (Nasdaq: ICPT) at Market Perform with a price target of $144 as OCA briefing docs were posted ahead of an FDA panel this week.
ANalyst Joseph Schwartz commented, the FDA briefing documents for obeticholic acid (OCA) were released this morning and are largely in line with our recently-outlined expectations (LINK) and we maintain our opinion that ICPT is likely to receive a positive panel vote on Thursday, 4/7, and secure approval in the primary biliary cholangitis (PBC) indication by... More
